Pluristem Wins Cell Therapy Patent Case in Europe; European

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pluristem Wins Cell Therapy Patent Case in Europe; European Patent Office Confirms Validity of Amended Claims

HAIFA, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq: PSTI ) (TASE: PLTR ), a leading developer of placenta-based cell therapy products, announced today that its European Patent No. EP2200622, titled, "ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY", was upheld by the European Patent Office in amended form, affirming its validity.

Pluristem's patent went through Opposition Proceedings before the Opposition Division of the European Patent Office, as a result of a challenge from a cell therapy company. The European Patent Office concluded that Pluristem's patent, whose claims cover treatment of ischemia with adherent placental cells which are propagated using a 3D culture, is valid.

"With a portfolio of 30 issued patents and another 120 pending, intellectual property is a core asset for Pluristem. We will continue to invest in and defend our patents," stated Zami Aberman, Chairman and CEO of Pluristem.

"We believe this case, which was brought to the Opposition Division of the European Patent Office from a cell therapy company, afforded Pluristem a clear opportunity. We have proven that we are determined to protect our IP assets that cover our unique, proprietary inventions, and that we are committed to protect our patents from any challenge," Aberman concluded.

About Opposition Proceedings before the European Patent Office (EPO)

EPO Opposition Proceedings are post-grant adversarial proceedings in which interested third parties can challenge the validity of all the national parts of a European patent via a single centralized procedure. The decision of the Opposition Division to uphold Pluristem's EP2200622 in amended form is open to an appeal to one of the EPO's Technical Boards of Appeal for all parties involved.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation or ischemia. PLX cells are grown using the Company's proprietary three dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com , the content of which is not part of this press release.

The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements when we discuss investing in and defending our patents. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may end up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Pluristem Therapeutics Inc.: Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 131

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 187

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 122

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 44

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 127

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 44

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading

Top 5 Most Recently Viewed Articles

New Research Grants Support Diet Impact on Health Outcomes

Updated Category News Views 85

New Research Grants Empower Understanding of Diet and Health Healthcare technology company Komodo Health has recently announced the recipients of its 2024 Diet-Related Health (DRH) grants. These grants are aimed at advancing research that explores the pivotal influence of diet on various health outcomes. Funded by the Robert Wood Johnson Foundation (RWJF), the DRH program...

Continue Reading
Innovative Cardiology Care with Dr. Butkevich's Hybrid Choice™

Updated Category News Views 118

Dr. Alexander Butkevich Introduces Hybrid Choice™ Concierge Program Patients in the Houston area can now access a unique cardiology service from Dr. Alexander Butkevich, MD, thanks to Concierge Choice Physicians. This innovative program provides enhanced connectivity and personalized care adjustments, catering to the evolving needs of patients. The Unique Benefits of...

Continue Reading
Revolutionizing Cryptocurrency with ALR MINER's AI Cloud Service

Updated Category News Views 274

Revolutionizing Cryptocurrency Mining ALR MINER has emerged as a pioneering force in the cryptocurrency world by launching a groundbreaking zero-cost AI cloud mining platform. This innovative approach gives users the opportunity to earn cryptocurrencies like Bitcoin, Ethereum, Dogecoin, and Ripple without any upfront costs, reshaping the way mining is perceived and...

Continue Reading
Instacart Positioned Well Amid Competition with Major Rivals

Updated Category News Views 279

Instacart's Competitive Landscape Instacart (NASDAQ:CART) has made a notable mark in the online grocery delivery sector, and analysts from Goldman Sachs believe its stock is already reflecting the ongoing competition. Despite challenges from giants like Amazon, Uber, and DoorDash, there are reasons to maintain a bullish outlook on Instacart. Supporting Recommendation from...

Continue Reading
Daily Mango Benefits: Heart Health Insights for Women

Updated Category News Views 238

Exploring Mango's Heart Health Benefits Mangos have long been celebrated for their vibrant flavor and nutritional perks. Recent studies now emerge, shedding light on the potential heart and metabolic health benefits of daily mango consumption, particularly for postmenopausal women. This demographic faces unique challenges as they navigate changes in their bodies and...

Continue Reading